Oct 23, 2026
San Diego, California Oct 22, 2026 (Issuewire.com) - Ting Therapeutics Advances TT004 into Phase Ib Clinical Trial as a Potential Chemoprotective Therapy for Cisplatin-Treated Patients
Ting Therapeutics, Inc., a biotechnology company developing therapies for treatment-related tissue injury, today announced that its lead candidate, TT004, has received IND approval in China and is advancing into Phase Ib clinical development as a potential chemoprotective therapy for patients receiving cisplatin chemotherapy.
Cisplatin is a highly effective cancer treatment, but its toxicities can substantially limit therapy. Approximately 40% of patients discontinue or modify chemotherapy because of treatment-related toxicities. Cisplatin can also cause permanent hearing loss in up to 80% of patients and acute kidney injury in approximately 30% of patients.
TT004 is designed to protect normal tissues from cisplatin toxicity while preserving its anticancer activity. In preclinical studies, TT004 increased survival following cisplatin exposure three-fold and reduced cisplatin-induced hearing loss and kidney injury by approximately 70%, without compromising cisplatin's anticancer effects.
"These findings support our vision of TT004 as a chemoprotective therapy that could improve the tolerability of cisplatin while maintaining its anticancer efficacy," said Jian Zuo, PhD, Co-Founder and CEO of Ting Therapeutics. "Our goal is to reduce the suffering caused by cisplatin treatment-related toxicities, help more patients receive and complete effective chemotherapy, and improve their long-term quality of life."
Ting Therapeutics recently licensed its China rights for TT004 to Rising Dragon, a Chinese biotechnology company, for development in China. The companies jointly developed TT004 as an oral tablet and obtained IND approval from China's Center for Drug Evaluation (CDE) for first-in-human clinical evaluation.
The Phase Ib trial, conducted in collaboration with oncologists and otolaryngologists at Eye and ENT Hospital of Fudan University in Shanghai, will evaluate the safety and tolerability of oral TT004 administered with standard-of-care cisplatin chemotherapy in patients with head and neck cancer. The study has received institutional ethics approval and is preparing to initiate patient recruitment.
TT004's protective effects have been demonstrated only in preclinical models and have not yet been shown in humans. This trial is the first clinical evaluation of TT004 and an important step toward determining whether these effects can be translated to cancer patients.
About Ting Therapeutics
Founded in 2018, Ting Therapeutics, Inc. develops novel and repurposed therapeutics to prevent and treat hearing loss and other treatment-related tissue injuries. The Company's pipeline targets hearing loss associated with chemotherapy, noise exposure, antibiotics, aging, and other causes.
Contact:
Jian Zuo, PhD, Co-Founder & CEO
Ting Therapeutics, Inc.
6868 Nancy Ridge Dr., San Diego, CA 92121
[email protected]
Source :Ting Therapeutics, Inc.
This article was originally published by IssueWire. Read the original article here.
CALAPAN CITY, Oriental Mindoro — The Department of the Interior and Local Government (DILG) Oriental Mindoro served the dismissal order issued by the Office of the Ombudsman against Baco, Oriental Mindoro Mayor Allan Roldan at around 5:00 p.m. on Thursday, Oct. 22. With the order served, Vice Mayor Eric Castillo has automatically assumed the position
SEC Chairman Francis Lim spearheads a daring undertaking into the realm of market making, in a bid to boost stock market trading in the Philippines
KORONADAL CITY, South Cotabato — The municipal government of Tampakan in South Cotabato has created a task force to prepare for the possible effects of Super El Niño, including drought, water shortages and damage to agricultural production. Mayor Leonard T. Escobillo issued Executive Order No. 37, series of 2026, creating the Tampakan El Niño Response
BACOLOD CITY — The National Food Authority (NFA) in Negros Occidental has intensified its palay procurement program to bolster its dwindling buffer stock, an official said on Thursday, Oct. 22. NFA Negros Occidental Branch Manager Cherrybeth Gevero said their buffer stock has critically dropped to one-day supply, far below the agency’s mandated 15-day reserve. To
At least 16 people were killed and 32 more injured when a strong 7.0-magnitude earthquake struck China's remote Tibet region, state news agency Xinhua said, citing local authorities.
MANILA, Philippines — The Philippines could lose up to P603 billion annually, or nearly 3% of its gross domestic product (GDP), to fraud involving money mule accounts, according to a joint whitepaper by trust tech company IDfy Philippines and Filipino credit bureau CIBI Information Inc. The report, “Mule Hunting: Are We Chasing Ghosts?,” examined Bangko
MANILA, Philippines — Refusing to compromise his independence in his bid for the top judicial post, Senior Associate Justice Marvic Leonen, during his public interview before the Judicial and Bar Council (JBC) underscored that high office must never come at the expense of judicial integrity. “I give no bribe or assurance to anyone about any
These bets are part of the list of candidates who vied for the justice post in 2025 that ultimately went to Associate Justice Raul Villanueva
Upon landing in the Little Red Dot, you'll be greeted by the world-class Changi Airport, named the World's Best Airport for 2026 by Skytrax for a second year in a row.
Mkini's probe finds alleged disturbing lack of action over the years.
BACOLOD CITY — Dengue-related fatalities in Negros Occidental have climbed to 23 as total infections reached 4,208, the Provincial Health Office (PHO) reported Thursday, Oct. 22. The figures from January 4 to October 17 show an overall drop of 17.57 percent or 879 fewer cases compared to the 5,105 cases reported during the same period
MANILA, Philippines — Fewer Filipinos closely followed the impeachment trial of Vice President Sara Duterte compared with past impeachment proceedings, the Social Weather Stations (SWS) reported. According to its survey conducted from Sept. 21 to 27, only 42 percent of adult Filipinos followed Duterte’s impeachment trial “very or somewhat” closely. The SWS said this was
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.